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Highly active antiretroviral therapy (HAART) has led to
dramatic changes in HIV disease. Patients are now living
for a significantly longer time; with increasing numbers
over the age of 60. Most have been living with HIV dis-
ease for many years, some in excess of 20 years. Addi-
tionally, the number of patients over 50 years old who
have recently acquired HIV infection is increasing.
Despite the benefits of HAART, cognitive impairment
remains. Whilst the incidence of HIV associated demen-
tia (HAD) has significantly fallen with HAART, its pre-
valence is increasing partly because patients are living
longer with fixed deficits. Furthermore, the prevalence
of milder cognitive impairment, now termed minor neu-
rocognitive disorder and included under the broader
term HIV-associated neurocognitive disorder (HAND),
has not changed despite the introduction of HAART.
While there are many potential reasons for this, there is
concern that the longer duration of HIV disease, as a
consequence of HAART, together with the increasing
age of infected persons may have a compounding detri-
mental effect on cognitive function. Additionally, these
two factors may facilitate and perhaps enhance the
expression of a variety of neurodegenerative diseases as
HIV-infected patients approach the age where such dis-
orders become increasingly common. This presentation
will review the evidence for the potential compounding
effect of age on cognition in HIV disease by examining
the evidence for persistent and developing neurodegen-
eration in HAART treated patients, particularly in those
maximal suppression of HIV viral load in the blood and
cerebrospinal fluid (CSF). Analysis of three different
cohorts has shown an approximate rate of HAND of
35% in patients with advanced HIV disease who are
virally suppressed. Evidence for the facilitation of neuro-
degenerative diseases by HIV and age, will also be
detailed. This primarily centres around evidence for the
development of an Alzheimer like illness and
Parkinsonism. This is followed by a delineation of the
potential mechanisms firstly by a review of the general
aspects of the pathogenesis of neurodegenerative dis-
eases. Then the effects of normal ageing and how they
intersect with HAND will be discussed, followed by a
review of the overlapping features and mechanisms in
HIV and neurodegenerative diseases. Lastly two poten-
tial therapeutic interventions, the rationale for optimis-
ing HAART to ensure adequate brain penetration of
antiretroviral drugs, and the clinical value of risk factor
reduction for neurodegenerative diseases will be
reviewed.
Published: 11 May 2010
doi:10.1186/1742-4690-7-S1-I7
Cite this article as: Brew: Neurodegeneration in the HAART era.
Retrovirology 2010 7(Suppl 1):I7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Department of Neurology, Level 4, Xavier Building, St. Vincent’s Hospital,
Victoria Street, Darlinghurst, Sydney, Australia
Brew Retrovirology 2010, 7(Suppl 1):I7
http://www.retrovirology.com/content/7/S1/I7
© 2010 Brew; licensee BioMed Central Ltd.
